NGUYÊN NHÂN BỎ TRỊ, ĐẶC ĐIỂM BÙNG PHÁT VI RÚT VÀ KẾT QUẢ SAU ĐIỀU TRỊ CỦA BỆNH NHÂN VIÊM GAN B MẠN BỎ TRỊ ĐƯỢC ĐIỀU TRỊ TẠI BỆNH VIỆN BỆNH NHIỆT ĐỚI TRUNG ƯƠNG (2018 - 2023)

Abstract

Objectives: Describe the causes of treatment withdrawal, characteristics of viral outbreaks and posttreatment outcomes of hepatitis B patients after treatment withdrawal.
Subjects and methods: Retrospective and prospective descriptive study on 336 patients with chronic hepatitis B who took Nucleos(t)ide analogue (NA). The patient did not comply with treatment instructions and stopped NA medicine.
Results and conclusions: CAntiviral drugs used before stopping treatment: 54.2% were TDF, 14.9% were ETV, 4.5% were TAF, 26.1% were unknown. Median duration of treatment was 24 months.  Reasons for discontinuing medication are: 7.1% improved liver function, 1.2% pregnancy, 3% not being able to buy medication due to COVID-19, 21.7% not understanding the treatment course, taking medication 1.2% of traditional medicines, 64.9% of reasons cannot be exploited. Patients who stopped
taking medication for more than 12 months accounted for 32.8%.
HBV DNA viral load increased above 10^6 copies/ml in patients who stopped for <6 months accounted for 55.2%, in patients who stopped for more than 12 months accounted for 32.2%, in patients who stopped for 6 - 12 months accounted for 55.2%. 12.6%.
Treatment: The number of patients receiving plasma exchange was 11 (3.3%), treatment worsened in 3.6%.